Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | AVPR1B | P47901 | 8/20 | 0.42 |
| ▸ | USP9X | Q93008 | 3/20 | 0.42 |
| ▸ | USP24 | Q9UPU5 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877470 | 0.89 | MMEL1 (0.59) | MMEL1EPHX2 | |
| SCHEMBL2873143 | 0.87 | MMEL1 (0.57) | MMEL1EPHX2 | |
| SCHEMBL10267558 | 0.82 | KDM4E (0.44) | TSHRKDM4ETP53AVPR1BALDH1A1 | |
| SCHEMBL2868857 | 0.82 | AVPR1B (0.48) | MMEL1TSHRKDM4ETP53AVPR1B | |
| SCHEMBL2873259 | 0.79 | MMEL1 (0.47) | MMEL1EPHX2 | |
| SCHEMBL2707583 | 0.77 | MMEL1 (0.47) | MMEL1EPHX2 | |
| SCHEMBL16975187 | 0.75 | MMEL1 (0.45) | MMEL1EPHX2 | |
| SCHEMBL15563643 | 0.75 | MME (0.48) | MMEL1EPHX2 | |
| SCHEMBL15564105 | 0.74 | MMEL1 (0.42) | MMEL1EPHX2ALDH1A1 | |
| SCHEMBL3706162 | 0.74 | MMEL1 (0.48) | MMEL1TSHRKDM4ETP53AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| US-8394853-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | MMEL1 299/4885TSHR 3209/4885KDM4E 2452/4885 |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | MMEL1 299/4885TSHR 3209/4885KDM4E 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.